Pharmacogenetics of hypersensitivity drug reactions
Tài liệu tham khảo
WHO World Health Organization, 1966, 425
Lazarou, 1998, Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies, JAMA, 279, 1200, 10.1001/jama.279.15.1200
2008
Ernst, 2001, Drug-related morbidity and mortality: updating the cost-of-illness model, J Am Pharm Assoc (Wash), 41, 192, 10.1016/S1086-5802(16)31229-3
Wysowski, 2005, Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions, Arch Intern Med, 165, 1363, 10.1001/archinte.165.12.1363
Rawlins, 1977, Pathogenesis of adverse drug reactions
Coombs, 1968, 575
Pichler, 2003, Delayed drug hypersensitivity reactions, Ann Intern Med, 139, 683, 10.7326/0003-4819-139-8-200310210-00012
Pichler, 2010, Drug hypersensitivity reactions: pathomechanism and clinical symptoms, Med Clin North Am, 94, 645, 10.1016/j.mcna.2010.04.003
Schnyder, 1997, Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones, J Clin Invest, 100, 136, 10.1172/JCI119505
Naisbitt, 2003, Characterization of drug-specific T cells in lamotrigine hypersensitivity, J Allergy Clin Immunol, 111, 1393, 10.1067/mai.2003.1507
Zanni, 1998, HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes, J Clin Invest, 102, 1591, 10.1172/JCI3544
Pavlos, 2014, Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy, J Allergy Clin Immunol Pract, 2, 21, 10.1016/j.jaip.2013.11.005
Hetherington, 2001, Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir, Clinical therapeutics, 23, 1603, 10.1016/S0149-2918(01)80132-6
Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet, 359, 1121, 10.1016/S0140-6736(02)08158-8
Mallal, 2002, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet, 359, 727, 10.1016/S0140-6736(02)07873-X
Hughes, 2004, Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity, Pharmacogenetics, 14, 335, 10.1097/00008571-200406000-00002
Rauch, 2006, Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study, Clin Infec Dis, 43, 99, 10.1086/504874
Waters, 2007, Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience, AIDS, 21, 2533, 10.1097/QAD.0b013e328273bc07
Zucman, 2007, Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population, J Acquir Immune Defic Syndr, 45, 1, 10.1097/QAI.0b013e318046ea31
Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135
Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenet Genomics, 16, 297, 10.1097/01.fpc.0000199500.46842.4a
Sousa-Pinto, 2015, Pharmacogenetics of abacavir hypersensitivity: a systematic review and meta-analysis of the association with HLA-B*57:01, J Allergy Clin Immunol, 136, 10.1016/j.jaci.2015.03.019
Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clin Pharmacol Ther, 92, 414, 10.1038/clpt.2012.96
Pavlos, 2015, T cell-mediated hypersensitivity reactions to drugs, Annu Rev Med, 66, 439, 10.1146/annurev-med-050913-022745
Yip, 2012, HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review, Clin Pharmacol Ther, 92, 757, 10.1038/clpt.2012.189
Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379
Migueles, 2000, HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors, Proc Natl Acad Sci U S A, 97, 2709, 10.1073/pnas.050567397
Fellay, 2007, A whole-genome association study of major determinants for host control of HIV-1, Science, 317, 944, 10.1126/science.1143767
UK Collaborative HIV Cohort Study Steering Committee, 2013, HLA B*5701 status, disease progression, and response to antiretroviral therapy, AIDS, 27, 2587, 10.1097/01.aids.0000432613.95455.71
Mockenhaupt, 2011, The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis, Expert Rev Clin Immunol, 7, 803, 10.1586/eci.11.66
Dao, 2015, Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms, Asia Pac Allergy, 5, 59, 10.5415/apallergy.2015.5.2.59
Harr, 2010, Toxic epidermal necrolysis and Stevens-Johnson syndrome, Orphanet J Rare Dis, 5, 39, 10.1186/1750-1172-5-39
Barbarino, 2015, PharmGKB summary: very important pharmacogene information for human leukocyte antigen B, Pharmacogenet genomics, 25, 205, 10.1097/FPC.0000000000000118
Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a
Chung, 2012, Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis, J Dermatol Sci, 66, 190, 10.1016/j.jdermsci.2012.04.002
Cheng, 2014, HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review, J Immunol Res, 2014, 565320, 10.1155/2014/565320
Man, 2007, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese, Epilepsia, 48, 1015, 10.1111/j.1528-1167.2007.01022.x
Tassaneeyakul, 2010, Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population, Epilepsia, 51, 926, 10.1111/j.1528-1167.2010.02533.x
Locharernkul, 2008, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population, Epilepsia, 49, 2087, 10.1111/j.1528-1167.2008.01719.x
Mehta, 2009, Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians, Indian J Dermatol Venereol Leprol, 75, 579, 10.4103/0378-6323.57718
Kulkantrakorn, 2012, HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain, Pain Pract, 12, 202, 10.1111/j.1533-2500.2011.00479.x
Grover, 2014, HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis, Pharmacogenet Genomics, 24, 94, 10.1097/FPC.0000000000000021
Tangamornsuksan, 2013, Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis, JAMA Dermatol, 149, 1025, 10.1001/jamadermatol.2013.4114
Bloch, 2014, Pharmacogenetics of antiepileptic drug-induced hypersensitivity, Pharmacogenomics, 15, 857, 10.2217/pgs.14.65
Chen, 2011, Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan, N Engl J Med, 364, 1126, 10.1056/NEJMoa1009717
Ozeki, 2011, Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population, Hum Mol Genet, 20, 1034, 10.1093/hmg/ddq537
McCormack, 2011, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297
Alfirevic, 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity, Pharmacogenomics, 7, 813, 10.2217/14622416.7.6.813
Niihara, 2012, HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population, J Dermatol, 39, 594, 10.1111/j.1346-8138.2011.01457.x
Hung, 2010, Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, Pharmacogenomics, 11, 349, 10.2217/pgs.09.162
Liao, 2011, HLA-B*1502 screening and toxic effects of carbamazepine, N Engl J Med, 365, 672, 10.1056/NEJMc1105467
Hershfield, 2013, Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing, Clin Pharmacol Ther, 93, 153, 10.1038/clpt.2012.209
Lee, 2014, Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity, Public Health Genomics, 17, 248, 10.1159/000366253
Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci U S A, 102, 4134, 10.1073/pnas.0409500102
Tohkin, 2013, A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients, Pharmacogenomics J, 13, 60, 10.1038/tpj.2011.41
Tassaneeyakul, 2009, Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population, Pharmacogenet Genomics, 19, 704, 10.1097/FPC.0b013e328330a3b8
Cao, 2012, HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese, Pharmacogenomics, 13, 1193, 10.2217/pgs.12.89
Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617
Kang, 2011, Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans, Pharmacogenet Genomics, 21, 303, 10.1097/FPC.0b013e32834282b8
Lonjou, 2008, A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharmacogenet Genomics, 18, 99, 10.1097/FPC.0b013e3282f3ef9c
Gonzalez-Galarza, 2015, Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations, Nucleic Acids Res, 43, D784, 10.1093/nar/gku1166
Phillips, 2010, Pharmacogenetics of drug hypersensitivity, Pharmacogenomics, 11, 973, 10.2217/pgs.10.77
Alfirevic, 2011, Drug induced hypersensitivity and the HLA complex, Pharmaceuticals, 4, 69, 10.3390/ph4010069
Becquemont, 2010, HLA: a pharmacogenomics success story, Pharmacogenomics, 11, 277, 10.2217/pgs.10.38